The other 5% of the adult pneumoccal-vaccine market is MRK's offering: Vaxneuvance (a/k/a V114) followed by MRK's 1980s product, Pneumovax (#msg-166441188). The need for two injections and two appointments is why MRK has only a 5% market share.
MRK has a newer vaccine, V116, which is not yet on the market but is slated to be a serious competitor to Prevnar-20 in the adult market (#msg-172452293).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.